Table 1.

Current status of licensed calcitonin gene-related peptide drugs in the UK

DrugDoseStatus
Erenumab (Aimovig®)70–140 mg monthlySubmitted and rejected by the National Institute for Health and Care Excellence (NICE) on the grounds of cost effectiveness. Accepted by the Scottish Medicines Consortium for chronic migraine, in whom three agents have failed
Fremanezumab (Ajovy®)225 mg monthly or 675 mg 3-monthlyAccepted by the Scottish Medicines Consortium and NICE for chronic migraine, in whom three agents have failed
Galcanezumab (Emgality®)120–240 mg monthlyAwaiting NICE submission